RT Journal Article
SR Electronic
T1 Decisive Conditions for Strategic Vaccination against SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.05.21252962
DO 10.1101/2021.03.05.21252962
A1 Böttcher, Lucas
A1 Nagler, Jan
YR 2021
UL http://medrxiv.org/content/early/2021/07/06/2021.03.05.21252962.abstract
AB While vaccines against SARS-CoV-2 are being administered, in most countries it may still take months until their supply can meet demand. The majority of available vaccines elicits strong immune responses when administered as prime-boost regimens. Since the immunological response to the first (“prime”) injection may provide already a substantial reduction in infectiousness and protection against severe disease, it may be more effective—under certain immunological and epidemiological conditions—to vaccinate as many people as possible with only one shot, instead of administering a person a second (“boost”) shot. Such a vaccination campaign may help to more effectively slow down the spread of SARS-CoV-2, reduce hospitalizations, and reduce fatalities, which is our objective. Yet, the conditions which make single-dose vaccination favorable over prime-boost administrations are not well understood. By combining epidemiological modeling, random sampling techniques, and decision tree learning, we find that single-dose vaccination is robustly favored over prime-boost vaccination campaigns, even for low single-dose efficacies. For realistic scenarios and assumptions for SARS-CoV-2, recent data on new variants included, we show that the difference between prime-boost and single-shot waning rates is the only discriminative threshold, falling in the narrow range of 0.01–0.02 day−1 below which single-dose vaccination should be considered.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLB acknowledges financial support from the SNF (P2EZP2\_191888), NIH (R01HL146552), and Army Research Office (W911NF-18-1-0345).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur source codes are publicly available at https://github.com/lubo93/vaccination. https://github.com/lubo93/vaccination